Deeptech
Deeptech is the newest thing I write about here, a broader personal interest alongside my day-to-day work on SATELYX. This category covers how deeptech companies actually earn investor trust: why boring, checkable revenue is beating ambitious foundation-model narratives in robotics funding, why a quantum-sensing startup backed by two rival defense primes is a harder signal to fake than a headline valuation, and why nine-figure rounds for chips, missiles, and satellites are starting to be structured like project finance instead of venture capital.
SATELYX still focuses primarily on space, but I see real overlap with the industries covered here. A lot of deeptech companies, whether in hardware, sensing, or manufacturing, have genuine opportunities in space too. More on what we’re building at satelyx.com.
The angle here is the same one I bring to the rest of this site: not what’s technically ambitious, but what a deeptech company has actually proven, and to whom.
Craif Is Taking Home-Market Proof to the Hardest Market
Craif has raised roughly $33 million to expand its urine-based cancer-detection business in the United States. The funding headline matters, but the more useful signal is where the company starts from: Craif says its miSignal test is already offered through more than 2,500 medical institutions and 4,500 pharmacies in Japan, with more than 110,000 tests performed. Its Series D announcement frames the round as an American expansion, not an attempt to create its first real market.
Pixxel's $100M Round Is a Bet on the Layer Above the Satellite
Pixxel just raised $100 million, the largest funding round yet reported for an Indian space-technology company. What makes the round interesting is not simply that a hyperspectral-imaging company raised a large Series C. It is that the money is explicitly going toward an intelligence layer, new sensing modes, sovereign systems and manufacturing capacity, all at once. Pixxel’s announcement says the round was co-led by Temasek and Seraphim, bringing total funding to $195 million.
When the Growth Round Comes After the Hardest Proof
Bridge to Life raised $110 million in August, but the number is less interesting than the sequencing. The company had already received FDA De Novo clearance for its VitaSmart liver-perfusion system in January. By the time the Series C and debt financing closed, the company was raising to expand commercial rollout and build its next products, not to find out whether its core system could clear its largest regulatory hurdle. Bridge to Life’s financing announcement makes that unusually explicit.
This Week's Deeptech Rounds Aren't All Made of the Same Money
Three deeptech companies announced funding this past week, and if you only read the headline numbers, they’d blur into the same story: hard-tech startup raises tens or hundreds of millions of dollars. Look at how each round is actually built, though, and they’re telling three different stories about who’s willing to bet on what, and how. One is half debt, collateralized against a backlog you can go check. One has no new investor in it at all, and the company says so itself. One isn’t venture capital in any conventional sense. The size of the check is the least interesting number in all three.
Physical AI's Real Bottleneck Isn't the Model, It's Everything Underneath It
Two deeptech rounds closed a few weeks apart this August, at wildly different sizes, and neither company would describe itself as making the other’s pitch. One says a robot’s problem isn’t that it can’t decide what to do, it’s that it can’t reliably tell what’s in front of it. The other says an AI chip’s problem isn’t the architecture on the die, it’s the material sitting between the transistors that decides how much heat the chip can shed before it throttles. Neither company is trying to build a smarter model. Both are betting the model layer is already ahead of what the physical layer underneath it can support.
The Difference Between a Checkable Claim and a Checked One
Two early-stage deeptech companies made news this month with claims worth checking against reality. One got there by getting two rival defense giants to independently decide it was worth backing before it had shipped a single unit. The other got there by naming a specific date on the calendar and daring anyone to hold it to that date. Both are legitimate ways to earn trust at the earliest stage of a company’s life. Only one of them has actually been tested yet.
When Deeptech's Biggest Rounds Start Looking Like Infrastructure Deals
Three deeptech companies closed nine-figure-plus rounds in the same few weeks this August, and the striking thing isn’t the size of any single check. It’s who’s writing them and how the money is structured. A UK sovereign fund and Arm backed a semiconductor startup’s chip architecture bet. A revolving credit facility, not just equity, is funding a missile-manufacturing campus. Google and Toyota’s venture arm are betting directly on satellite production capacity, not just the data those satellites collect. None of this looks like the venture capital playbook from ten years ago. It looks a lot more like project finance.
In Robotics Funding Right Now, Boring Beats Brilliant
Two robotics companies raised roughly $200 million each in the same stretch of August, and only one of them can point to trucks already running on real customer routes with no one behind the wheel. The other raised its $200 million on the promise that a single model will eventually drive, walk, or grip its way across just about any robot body you hand it. Both bets might turn out fine. But they are not the same bet, and the gap between them is the clearest read yet on what “boring” actually buys a hardware founder right now.